A fresh shine on cystic fibrosis inhalation therapy: Antimicrobial synergy of polymyxin B in combination with silver nanoparticles

Raad Jasim, Elena K. Schneider, Meiling Han, Mohammad A.K. Azad, Maytham Hussein, Cameron Nowell, Mark A. Baker, Jiping Wang, Jian Li, Tony Velkov

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung. The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxinsusceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥ 4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥ 2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone. The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.

Original languageEnglish
Pages (from-to)447-457
Number of pages11
JournalJournal of Biomedical Nanotechnology
Volume13
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Antibiotic combination
  • Cystic fibrosis
  • Nanoparticles
  • Polymyxin
  • Silver

Cite this

@article{669a06e830f44a078bcc453807f91945,
title = "A fresh shine on cystic fibrosis inhalation therapy: Antimicrobial synergy of polymyxin B in combination with silver nanoparticles",
abstract = "This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung. The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxinsusceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥ 4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥ 2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone. The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.",
keywords = "Antibiotic combination, Cystic fibrosis, Nanoparticles, Polymyxin, Silver",
author = "Raad Jasim and Schneider, {Elena K.} and Meiling Han and Azad, {Mohammad A.K.} and Maytham Hussein and Cameron Nowell and Baker, {Mark A.} and Jiping Wang and Jian Li and Tony Velkov",
year = "2017",
month = "4",
day = "1",
doi = "10.1166/jbn.2017.2355",
language = "English",
volume = "13",
pages = "447--457",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "4",

}

A fresh shine on cystic fibrosis inhalation therapy : Antimicrobial synergy of polymyxin B in combination with silver nanoparticles. / Jasim, Raad; Schneider, Elena K.; Han, Meiling; Azad, Mohammad A.K.; Hussein, Maytham; Nowell, Cameron; Baker, Mark A.; Wang, Jiping; Li, Jian; Velkov, Tony.

In: Journal of Biomedical Nanotechnology, Vol. 13, No. 4, 01.04.2017, p. 447-457.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A fresh shine on cystic fibrosis inhalation therapy

T2 - Antimicrobial synergy of polymyxin B in combination with silver nanoparticles

AU - Jasim, Raad

AU - Schneider, Elena K.

AU - Han, Meiling

AU - Azad, Mohammad A.K.

AU - Hussein, Maytham

AU - Nowell, Cameron

AU - Baker, Mark A.

AU - Wang, Jiping

AU - Li, Jian

AU - Velkov, Tony

PY - 2017/4/1

Y1 - 2017/4/1

N2 - This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung. The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxinsusceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥ 4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥ 2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone. The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.

AB - This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung. The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxinsusceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥ 4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥ 2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone. The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.

KW - Antibiotic combination

KW - Cystic fibrosis

KW - Nanoparticles

KW - Polymyxin

KW - Silver

UR - http://www.scopus.com/inward/record.url?scp=85018736175&partnerID=8YFLogxK

U2 - 10.1166/jbn.2017.2355

DO - 10.1166/jbn.2017.2355

M3 - Article

AN - SCOPUS:85018736175

VL - 13

SP - 447

EP - 457

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 4

ER -